Thus, SGLT2 inhibitors can alleviate glomerular filtration in the early stage of diabetic nephropathy, reduce albuminuria, and delay the decline of renal function for a long time (Cherney et al., 2014; Škrtić and Cherney, 2015). This evidence concerns the gene SLC5A2 and diabetic kidney disease.